Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BretRosenthal Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::30246985.png) ARMR Investing [@BretRosenthal](/creator/twitter/BretRosenthal) on x 2725 followers
Created: 2025-07-21 12:16:00 UTC

$BMY Bristol-Myers supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis accepted for review across four regions globally (47.36 )


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947269327251497126/c:line.svg)

**Related Topics**
[investment](/topic/investment)
[$bmy](/topic/$bmy)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/BretRosenthal/status/1947269327251497126)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

BretRosenthal Avatar ARMR Investing @BretRosenthal on x 2725 followers Created: 2025-07-21 12:16:00 UTC

$BMY Bristol-Myers supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis accepted for review across four regions globally (47.36 )

XXX engagements

Engagements Line Chart

Related Topics investment $bmy stocks healthcare

Post Link

post/tweet::1947269327251497126
/post/tweet::1947269327251497126